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Interferon (IFN) was introduced into the treatment of follicular
lymphoma almost 20 years ago, on the basis of interesting data in
L1210 leukaemia and AKR lymphoma (Gresser et al, 1970, 1976)
but with limited understanding of its mode of action. Phase II
studies, using an empirical dose and schedule derived from the
original trial in osteogenic sarcoma (Strander et al, 1979) showed a
response rate of 30–50%, regardless of the source of interferon
(Gutterman et al, 1980; Louie et al, 1981; Foon et al, 1984; Quesada
et al, 1984; Horning et al, 1985; O’Connell et al, 1986; Wagstaff 
et al, 1986; Leavitt et al, 1987). The remissions were virtually
always incomplete and often took several months to achieve.
Further pre-clinical data suggested synergy between interferon and
conventional cytotoxic drugs (Chirigos and Pearson, 1973; Gresser
et al, 1978; Balkwill and Moodie, 1984) and the latter observations
formed the rationale for evaluating the combination of IFN 
and Chlorambucil (CB) in patients with low-grade lymphoma.
Feasibility was demonstrated in patients with recurrent or refrac-
tory disease and responses were observed in patients deemed to be
refractory to CB alone (Chisesi et al, 1987; Rohatiner et al, 1987).
A randomized study was therefore designed to evaluate the use of
IFN in 2 settings: in addition to CB as initial therapy, and as main-
tenance therapy in newly diagnosed patients with advanced
disease. The results form the basis of this report. 
PATIENTS AND METHODS 
Patients 
231 newly diagnosed patients with Stage III or IV follicular
lymphoma whose clinical characteristics at presentation are shown
in Table 1 were entered into the study between October 1984 and
October 1994. Patients were treated at 3 main centres: the Christie
Hospital, Manchester (104 patients), St. Bartholomew’s Hospital,
London (60 patients), and Queen Elizabeth Hospital, Birmingham
(22 patients). 18 patients were referred from other hospitals. 204
patients form the basis of this analysis, 27 having been excluded
for the following reasons: incorrect histology on review: 14, incor-
rect stage on review: 10, previous treatment: 3. 
Stage had been determined from the history, accompanied by
clinical examination, computed axial tomography (CT) of the chest,
abdomen and pelvis, and unilateral iliac crest bone marrow aspirate
and biopsy. Liver involvement was diagnosed on the basis of confir-
mation of defects seen on CT scanning by ultrasonography. 
Treatment 
The overall strategy is outlined in Figure 1. After informed
consent had been obtained, patients were randomly allocated to
receive either, CB: 10 mg daily for 6 weeks, followed by a 2-week
interval, with 3 subsequent 2-week treatment periods at the same
dose, separated by 2-week intervals or the latter given concur-
rently with IFN. Patients randomized to CB + IFN, received the
latter at a dose of 3 ´ 106 units thrice weekly, subcutaneously,
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were randomized to CB alone, 104 to the combination. 
CB or CB + IFN was discontinued for 2 weeks in the first
instance in patients with treatment-induced neutropenia (neutrophils
< 1 ´ 109 l–1) or thrombocytopenia (platelets < 100 ´ 109 l–1) and
restarted at full dosage upon recovery. Persistent or recurrent
cytopenia led to a 50% reduction in the CB dose, or ultimately to
discontinuation of therapy. Intolerable subjective side-effects attrib-
utable to IFN were managed in the first instance by a 50% dose
reduction and if they persisted, by discontinuation. 
For the first 2 years of the study, patients with responding or
‘stable’ disease were randomized to maintenance IFN or to no
further treatment, following stratification for response. Subse-
quently, randomization was limited to patients in whom a
complete or ‘good partial response’ (GPR) was achieved (see
below), it being considered more appropriate to administer alter-
native treatment to those in whom less than GPR was achieved.
Maintenance IFN (at the same dose and schedule as used initially)
was given for one year, except at the Christie Hospital, where it
was stopped after 6 months. Outcome (in terms of remission dura-
tion and survival) was the same, irrespective of the length of time
for which maintenance IFN was given, the results have therefore
been combined. 
108 of 126 eligible patients were randomized, 18 were not, for
the following reasons: error; 6, prior IFN toxicity; 5. 4 patients
declined randomization, and 1 developed recurrent lymphoma
within 4 weeks of finishing initial treatment. In 2 patients, second
randomization was considered inappropriate (due to persistent
neutropenia, and the development of angina respectively). The
number of patients actually receiving CB or the combination,
followed by IFN or no further treatment is shown in Table 2. 
Patients were seen every 2 weeks whilst receiving Chlorambucil
and monthly whilst receiving maintenance IFN (or being managed
expectantly if randomized to this arm of the study). Subsequently,
all patients were seen at 3 monthly intervals. Management follow-
ing recurrence was determined by the circumstances: in younger
patients, further chemotherapy was given to induce second remis-
sion with a view to proceeding to myeloablative therapy supported
by autologous bone marrow transplantation (Rohatiner et al,
1994). 
Post-treatment evaluation and definition of response 
Formal re-evaluation comprising clinical examination, CT scan-
ning and repeat bone marrow biopsy (if previously positive) was
undertaken one month after completion of initial treatment (unless
there was a clinical indication to do so earlier). 
Response was defined as either: complete remission (CR): no
evidence of residual disease; good partial remission (GPR): 
clinical complete response with minimal residual abnormality on 
CT scans or bone marrow trephine; poor partial remission 
(PPR): >50% reduction in any measurable lesion associated with
improvement in nonmeasurable involvement, i.e. less than GPR;
failure to respond: anything less than PPR. 
Statistical analyses 
In the original study protocol, it was considered necessary to
accrue 200 patients in order to demonstrate a difference in remis-
sion duration of 35–40%. The following factors were tested for
possible influence on response, remission duration and survival:
gender, age, presence of B symptoms, hepatosplenomegaly, stage,
anaemia (Hb < 11.5 g), abnormalities of liver function, perfor-
mance status and treatment with IFN. 
Randomization balance 
The study was randomized to achieve balance between the treat-
ment groups for both known and unknown prognostic factors.
Each variable (other than age) was therefore considered against
the randomization code. Balance for age (the only continuous vari-
able) was considered by looking at the median for each random-
ization group. 
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R
IFN: 3 ´ 106 units /day, ´ 3 / wk. s / cut.
IFN: DOSE AND SCHEDULE AS ABOVE, FOR 1 YEAR
NO FURTHER TREATMENT
key: CB: 10 mg/day
R
CB
CB
Figure 1 Treatment strategy 
Table 1 Clinical features at presentation 
CB CB + IFN Total 
M:F 49:51 62:42 111:93 
Age median (range) 53 (29–78) 51 (25–81) 52 (25–81) 
Stage IIIA 17 17 34 
IIIB 8 6 14 
IVA 42 47 89 
IVB 33 34 67 
Hepatomegaly 14 21 35 
Splenomegaly 36 36 72 
*This study was conducted at hospitals that used the Kiel classification. No
differentiation has therefore been made between histological subsets of
follicular lymphoma. 
Table 2 Numbers of patients at each randomization 
Initial therapy 2nd randomization 
IFN NFT 
CB 33 29 
CB + IFN 27 19 
Total 60 48 
NFT = No further treatment. Predicting response 
Variables were considered one at a time by calculating Fisher’s
exact test on tables of the variable vs response. Variables found to
be significant at P < 0.1 were put into a logistic model, together
with liver function (to adjust for balance). Only liver function and
variables with P < 0.05 were retained. Results of the logistic
regression analysis are given in terms of Odds ratios, an Odds ratio
of 2 for Hb (normal vs low) being interpreted as a patient with a
normal Hb having twice the chance of response as a patient with a
low Hb, all other prognostic factors being the same. 
Remission duration analysis 
Remission duration was defined as the time from date of response
to date of recurrence and was considered only for those patients in
whom CR or GPR was achieved. Univariate analysis was
performed by means of the Log-rank test and survival plots drawn
using the Kaplan–Meier method (Kaplan and Meier, 1958). All
variables significant at P < 0.1 in the log-rank analysis were put
into a backward stepwise Cox Regression model (Kaplan and
Meier, 1958). The proportional hazards model assumption was
assessed by means of log minus log hazard plots. The Cox results
are expressed in terms of hazard ratios, a hazard ratio of 2 for
anaemia again being interpreted as a patient with anaemia having
twice the risk of recurrence as a patient with a higher Hb, all other
prognostic factors being the same. 
Survival 
Survival was defined as the time from first randomization until
death, or last follow-up. Analyses were performed using the same
methods as described above for remission duration. 
RESULTS 
Response (Table 3) 
The overall response rate was 78% (161/204), CR being achieved
in 24% of patients (49/204). For patients who received CB as
initial treatment, the overall response rate was 84% (84/100), for
those receiving CB + IFN it was 74% (77/104). However, the CR
+ GPR rate was higher in patients receiving Chlorambucil alone
(70/100, 70% vs 56/104, 54%, P = 0.02). 
Univariate analysis using the Fisher Exact test showed gender,
B symptoms, performance status, liver function, anaemia, age and
treatment to predict for response. The final logistic (multivariate)
model on 183 patients with complete data is shown in Table 4.
‘Forcing’ the first randomization code into this model, the odds
ratio for CB + IFN vs CB alone is 0.5 (with a 95% confidence
interval of 0.2–1.1, P = 0.1). The addition of IFN to CB as initial
treatment did not therefore improve response rate. 
Duration of remission 
Since for most of the duration of the study, only patients in whom
CR or GPR was achieved (the majority) continued in the study (the
rest receiving alternative therapy), only this sub-group has been
included in the analysis of remission duration. With a median
follow-up of 8.5 years, the median remission duration is 3.8 years
(Figure 2); 88 patients have developed recurrent lymphoma. 2
patients died in remission, the latter have therefore been censored. 
On univariate analysis, lymph node enlargement, anaemia and the
addition of IFN were significant prognostic factors (liver function
being included for adjustment). When liver function was included in
the Cox model, no variable was found to be significant (Table 5).
‘Forcing’ liver function and the addition of IFN into the Cox model
(on 116 patients with 78 recurrences) gives a hazard ratio for CB +
IFN vs CB of 0.7 (95% confidence interval 0.4–1.1, P = 0.09). On
multivariate analysis, adjusting for potentially unbalanced factors
and for other prognostic factors, the addition of IFN to CB as the
initial treatment did not significantly influence remission duration. 
Survival 
The median survival was 8.5 years (Figure 2); 93 patients have
died, 70 as a consequence of disease progression, 10 of the latter
dying of complications of further treatment. 12 patients died of
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Table 3 Outcome of initial therapy 
CB CB + IFN TOTAL 
CR 28 (28%) 21 (20%) 49 (24%) 
GPR 42 (42%) 35 (34%) 77 (38%) 
PPR 14 (14%) 21 (20%) 35 (17%) 
Treatment failed 16 (16%) 27 (26%) 43 (21%) 
Total 100 104 204
Table 4 Prognostic factors for response 
Variable Coding OR (95% CI) P
value 
Gender F vs M 2.3 (1.0–5.2) 0.04 
Liver function poor vs normal 0.4 (0.2–0.95) 0.04 
Performance status change of one level 0.5 (0.3–0.9) 0.03 
Age 10-year difference 0.7 (0.5–1.0) 0.05 
OR = odds ratio; CI = confidence interval. 
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Figure 2 Survival and duration of remission for all patients 
Table 5 Prognostic factors for remission duration 
Variable Coding HR (95% CI) P value 
Liver function poor vs normal 1.4 (0.8–2.2) 0.2 
1st. randomization CB + IFN vs CB 0.76 (0.4–1.1) 0.09 
HR = hazard ratio; Cl = confidence interval. causes unrelated to lymphoma or its treatment (myocardial 
infarction 4, other malignancies 4, cerebrovascular accident 2,
haemorrhage 1, pulmonary embolism 1). 
On univariate analysis, B symptoms, liver function, perfor-
mance status, splenomegaly, anaemia and age were significant
prognostic factors. The final Cox model results (on 183 patients
with 82 deaths) are shown in Table 6. ‘Forcing’ the addition of
IFN into this model gives a hazard ratio for CB + IFN vs CB of
1.00, (95% confidence interval 0.64–1.6, P = 1.0). On multivariate
analysis, adjusting for potentially unbalanced factors and for other
prognostic factors, the addition of IFN to CB as initial treatment
did not influence survival. 
Effect of maintenance IFN on remission duration 
Complete or good partial remission was achieved in 126 patients
who were therefore eligible for second randomization. 108/126
were actually randomized, 60 to receive maintenance IFN, 48 to
no further treatment. Overall, 74 patients developed recurrent
lymphoma; 2 who died without recurrence are censored. 
On univariate analysis, none of the factors considered were
significant. On multivariate analysis, ‘forcing’ the use of mainte-
nance IFN into a Cox model gives a hazard ratio (for no further
treatment vs IFN maintenance) of 1.4, (95% confidence interval
0.9–2.2, P = 0.1). The use of maintenance IFN did not therefore
significantly influence remission duration. Considering the 4
possible treatment combinations resulting from the first and second
randomizations, (analysing 108 patients with 74 recurrences in a
Cox model) no sequence of treatments was significantly better in
terms of remission duration than CB followed by no further treat-
ment. These results are shown in full in Table 7 and in Figure 3. 
Effect of maintenance IFN on survival 
Once more, only patients in whom CR or GPR was achieved were
considered. Survival from second randomization was analysed
using the same methods as described above for analysis of survival
from the time of diagnosis. On univariate analysis, liver function,
anaemia and age were found to be significant prognostic factors.
On multivariate analysis, (using the Cox model on 108 patients
with 34 deaths), only age gave a hazard ratio of 1.6 (confidence
interval 1.2–2.2, P = 0.003). ‘Forcing’ the second randomization
into this model gives a hazard ratio for IFN maintenance vs no
further treatment of 1.5 (95% confidence interval 0.7–2.9, P =
0.3). The use of maintenance IFN did not therefore significantly
influence survival. Considering all 4 treatment combinations in the
Cox model, no combination was significantly better in terms of
survival than standard treatment with CB followed by no further
treatment (Table 8). Survival curves for the 4 patient groups are
shown in Figure 4. 
Toxicity 
7 patients had to discontinue CB due to clinical toxicity. All subse-
quently developed recurrent lymphoma; 4 are well, 3 died of
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Table 7 Cox model results for 4 treatment combinations in terms of
remission duration 
Treatment HR (95% Cl) P
value 
CB + IFN ® NFT vs CB ® NFT 0.8 (0.4–1.5) 0.4 
CB ® IFN vs CB ® NFT 0.7 (0.4–1.3) 0.2 
CB + IFN ® IFN vs CB ® NFT 0.6 (0.3–1.1) 0.09 
NFT = no further treatment; HR = hazard ratio; Cl = confidence interval. 
Table 8 Cox model results for 4 treatment combinations in terms of survival 
Variable Coding HR (95% Cl) P value 
Age 10-year difference 1.6 (1.2–2.2) 0.003 
Treatment CB + IFN ® NFT vs CB ® NFT 1.5 (0.6–3.9) 0.4 
CB  ® IFN vs CB ® NFT 0.8 (0.3–1.9) 0.6 
CB + IFN ® IFN vs CB ® NFT 0.8 (0.3–2.2) 0.7 
NFT = no further treatment; HR = hazard ratio; Cl = confidence interval. 
Table 6 Prognostic factors for survival 
Variable Coding HR (95% Cl) P value 
Liver function poor vs normal 1.9 (1.2–3.0) 0.005 
Performance status change of one level 1.6 (1.2–2.3) 0.005 
Age 10-year difference 1.5 (1.2–1.9) <0.001 
HR = hazard ratio; Cl = confidence interval. 
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© 2001 Cancer Research Campaignprogressive disease. Subjective Interferon toxicity with the initial
treatment prevented continuation of the drug in 9 patients. 6 of the
latter remain alive, 3/6 having been treated for recurrent lympho-
ma, 3 patients have died of progressive disease. 
Haematological toxicity, resulting in an interruption in treat-
ment or dose modification was significantly greater in patients
receiving the combination (11/100: CB alone vs 37/104 for CB +
IFN, P < 0.001). In addition, 5 patients experienced haematolog-
ical toxicity with maintenance IFN necessitating interruption of
treatment. 
DISCUSSION 
This study was undertaken to determine whether IFN, given ini-
tially in combination with, and then subsequent to, Chlorambucil,
would alter the clinical course of patients with follicular lym-
phoma. Disappointingly, this objective was not achieved, no signif-
icant advantage being demonstrated for the addition of IFN to
initial treatment or as maintenance therapy. An interim analysis had
shown a significant difference in remission duration in favour of
maintenance IFN (Price et al, 1991), however, with longer follow-
up, this difference has been abrogated. 
With regard to improving response rate, in this study, the addi-
tion of IFN not only did not help, but was associated with a lower
response rate. The explanation for this may be the greater degree of
haematological toxicity incurred with the combination, which in
turn resulted in delays in administering Chlorambucil. Neither of
the 2 other published studies in which IFN has been combined with
an alkylating agent has in fact shown any advantage for the combi-
nation (Chisesi et al, 1991; Peterson et al, 1997). In contrast, the
study reported by the ‘GELF’ Group (Solal-Celigny et al, 1993),
did show a significantly higher response rate for IFN given with a
more intensive, Adriamycin-containing regimen. 
The rationale for adding IFN to alkylating agent therapy was
based on 2 murine studies. Early work in AKR mice had demon-
strated an ‘additive’ effect with a 200% increase in survival for
mice treated with the combination of IFN and Cyclophosphamide
(Gresser et al, 1978). A subsequent study (using the same combina-
tion of drugs) in a breast cancer xenograft growing in nude 
mice confirmed a synergistic response (Balkwill and Moodie,
1984). The latter study also indicated that the antitumor effect was
greatest when the 2 drugs were used concurrently rather than
sequentially. 
The precise mechanisms of action of IFN in follicular lympho-
ma are unclear but probably represent a direct anti-proliferative
effect (Balkwill and Taylor-Papdimitriou, 1978; Balkwill et al,
1978, Taylor-Papdimitriou, 1980). It is, however, possible that
indirect effects on drug metabolism (Friedman et al, 1979; Singh
and Renton, 1981; Marguett et al, 1983; Stolfi et al, 1983) are also
involved. 
Although it was not the case in the present study, as mentioned
above, the use of IFN as part of initial treatment has been found to
prolong remission duration (Smalley et al, 1992; Solal-Celigny 
et al, 1993; Anderson and Smalley, 1993; Solal-Celigny, 1997; Arranz
et al, 1998) and in the ‘GELF’ study, survival (Solal-Celigny et al,
1993). However, the latter study also had a maintenance phase, it is
therefore difficult to separate out the influence of continuing IFN
from that of adding IFN to the initial therapy. With regard to
prolongation of survival in the ‘GELF’ study, the question as 
to whether this reflects delay in time to transformation (to large 
B-cell histology), or a reduction in the incidence of transformation
has been addressed; the rate of transformation was the same in the
2 treatment arms (Solal-Celigny, 1997). 
Some studies were specifically designed to evaluate the use of
maintenance IFN. Neither of the 2 other trials in which IFN mainte-
nance followed treatment with an alkylating agent (Chlorambucil
or Cyclophosphamide) show any advantage for maintenance IFN
(Chisese et al, 1991; Peterson et al, 1997). However, in a trial
conducted by the European Organization for the Research and
Treatment of Cancer, in which initial treatment comprised
Cyclophosphamide, Vincristine and Prednisolone (CVP, with or
without radiotherapy to large nodal masses), there was a trend
towards improved time to progression in the IFN–treated group
but this did not reach statistical significance (Hagenbeek et al,
1998). This was not the case in a study from Spain (Arranz et al,
1998), in which patients received CVP +/–IFN followed by a
second randomization to IFN or to no further treatment. The
German Low-grade Lymphoma Study Group trial (Unterhalt et al,
1996) does show a significant prolongation of disease-free
survival with maintenance IFN (following initial therapy with
either Prednimustine and Mitoxantrone, or CVP). However, this
study is different from the rest; there being no fixed time limit for
treatment with IFN, the drug being given until recurrence. In
contrast, in the present study, there was in fact no difference in
outcome between patients treated at the Christie Hospital where
maintenance IFN was given only for 6 months and those treated at
St Bartholomew’s Hospital where IFN was continued for 1 year
(data not shown). 
A Mexican study also shows both remission duration and
survival to be significantly longer in a group of patients random-
ized to receive IFN after CR had been achieved with 3 sequential
regimens followed in most patients by radiotherapy (Aviles et al,
1996). The obvious exception to these positive results is the trial
conducted by the South-West Oncology Group (SWOG), in which
the use of maintenance IFN given after the intensive, Adriamycin-
containing regimen ‘PROMACE-MOPP’ (and in some patients,
involved field radiotherapy) did not influence remission duration
or survival (Fisher et al, 2000). 
With regard to prognostic factors, the addition of Interferon did
not confer benefit in any particular group. (It was not possible to
assess the influence of a high LDH level, since LDH was not
routinely measured at the time that this study began.) Older age was
the only factor that correlated significantly with worse survival, in
agreement with most previous analyses (Rudders et al, 1979;
Gospodarowicz et al, 1984; Kantarjian et al, 1984; Gallagher et al,
1986; Lawrence et al, 1988; Steward et al, 1988; Lepage et al, 1990;
Leonard et al, 1991; Romaguera et al, 1991; Soubeyran et al, 1991). 
The discrepancies between the various studies may to some
extent be explained by variations in study design and differences
in selection criteria. Some trials included patients with low-grade
lymphoma, but not necessarily only follicular lymphoma. In some,
for example the ‘GELF’ study (Solal-Celigny et al, 1993), only
patients considered to have an adverse prognosis were eligible,
whereas in contrast, the ECOG study included patients with ‘indo-
lent disease’ who were treated at the time of diagnosis, irrespective
of whether there was a specific indication for treatment (Smalley
et al, 1992). 
In general however, the studies with the best results are those in
which Interferon has been combined with, or followed, relatively
intensive, initial chemotherapy (Smalley et al, 1992; Solal-Celigny
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study clearly being an exception (Fisher et al, 2000). The cumula-
tive dose of IFN may also be important; the ‘GELF’ (Solal-
Celigny et al, 1993), Mexican (Aviles et al, 1996) and German
(Unterhalt et al, 1996) studies used a cumulative dose higher than
that used in most of the others. 
In order to clarify these discrepancies, a meta-analysis of 8
randomized trials has been conducted (Rohatiner et al, 1998).
Only patients with follicular lymphoma were considered. No
significant advantage was demonstrated for the addition of IFN to
initial treatment. The use of IFN as part of initial therapy or as
maintenance therapy did significantly improve remission duration
(P = 0.001) and survival (P = 0.002) but there was significant
heterogeneity between studies. This was clarified when it became
apparent that the improvement was only true for studies in which a
relatively intensive, Adriamycin (or equivalent) containing initial
chemotherapy was used. With regard to ‘dose intensity’, in studies
using > 36 ´ 106 units of IFN per month, or a total cumulative dose
>1000  ´ 106 units, the addition of IFN significantly improved
survival, but this effect ‘lost’ significance when the intensity of
initial chemotherapy was included in a multivariate regression
analysis (Gregory, 1999). Thus, the meta-analysis results confirm
the impression that IFN is most effective when used with, or
following, more intensive chemotherapy. 
These results need to be seen within the context of other current
experimental strategies for follicular lymphoma. High-dose treat-
ment with autologous haemopoietic cell support (Rohatiner et al,
1994; Freedman et al, 1997, 1999; Apostolidis et al, 1999, 2000),
Fludarabine-containing regimens that may induce ‘molecular remis-
sion’ (McLaughlin et al, 1996; Crawley et al, 2000; Grillo-Lopez
et al, 2000), antibody therapy (McLaughlin et al, 1998; Rogers et
al, 1996) and targetted irradiation (Press et al, 1995, Kaminski et
al, 1996, Vose et al, 2000) are currently being evaluated. It is
against this overall background that the place of Interferon must be
considered. 
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